How to Dose GHK-Cu

Key Takeaways

• The Body Pharm GHK-Cu pen is prefilled and dials the dose directly in milligrams — there is no powder to reconstitute, no bacteriostatic water, and no draw-up volume to calculate.
• Standard subcutaneous GHK-Cu dosing for UK research sits at 0.5–2 mg/day across 4–8 week cycles, with dose stratified by research endpoint (skin, wound healing, anti-inflammatory, hair).
• The pen holds 50 mg of GHK-Cu in a 3 mL cartridge; because you dial the dose in mg, the internal concentration is a manufacturing detail, not a number you dose against.
• Cycle 4–8 weeks on followed by 2–4 weeks washout to manage copper homeostasis and prevent receptor desensitisation.
• No published human subcutaneous randomised controlled trial exists as of 2026; all dosing derives from animal models, cell culture, and practitioner protocols.
• Rotate injection sites daily across abdomen, thigh, and flank to prevent lipodystrophy and maintain consistent absorption.

---

For UK research applications, GHK-Cu peptide is typically dosed subcutaneously at 0.5–2 mg/day across 4–12 week cycles, with the exact range tied to the research endpoint being modelled. No published human subcutaneous trials exist as of 2026 [2], so the table below maps practitioner-cited ranges to specific endpoints (skin, wound healing, anti-inflammatory work, and hair) alongside cycle conventions extrapolated from GHK-Cu's short plasma half-life of roughly 5–30 minutes [2][5].

This guide covers the standard subcutaneous dosing range for GHK-Cu research (0.5–2 mg/day), how the prefilled pen is dialled and stored, and how to structure on-cycle and washout periods based on published practitioner protocols and mechanistic rationale.

What Is GHK-Cu and Why Does Dosing Matter?

GHK-Cu is glycyl-L-histidyl-L-lysine copper(II), a naturally occurring human plasma tripeptide that binds copper with high affinity and modulates wound repair, anti-inflammatory signalling, and extracellular matrix remodelling [2]. The molecule was first isolated from human plasma in 1973 and has since been characterised across skin regeneration, hair follicle stimulation, and tissue repair models [2][8].

Endogenous plasma GHK concentrations fall sharply with age, which is the mechanistic rationale most provider literature uses to justify exogenous research dosing [8]. Pickart and colleagues have reported levels of roughly 200 ng/mL in young adults declining to under 80 ng/mL by age 60 — endogenous context, not a dosing target [unverified]. No published human subcutaneous trial has reproduced or targeted these plasma levels with injection protocols as of 2026 [2].

Why dose precision matters

Copper is biologically active at low concentrations, and the GHK carrier is what makes it bioavailable to tissue [2]. Under-dosing risks sub-therapeutic exposure in research endpoints with already short pharmacokinetic windows (plasma half-life ≈5–30 minutes [2][5]). Over-dosing introduces the theoretical concern of cumulative copper load, though no GHK-Cu-specific ceruloplasmin or serum copper shifts have been measured at 0.5–3 mg/day SC ranges [unverified]. Some researchers worry that stacking GHK-Cu with other repair peptides could compound copper exposure; cross-reference the BPC-157 and TB-500 dosing protocol and the broader peptide guides and dosing protocols index before finalising a regimen.

GHK-Cu is supplied in the UK as a research-use-only peptide; it is not an MHRA-licensed medicinal product, and nothing in this guide constitutes clinical advice [unverified][10].

GHK-Cu Dosing Protocol at a Glance (2026)

The standard subcutaneous GHK-Cu research dose is 1–2 mg once daily, cycled 4–8 weeks on and 2–4 weeks off, with 0.5 mg as a low-end exploratory anchor and 2 mg as the upper range cited in current provider protocols [1][5][8]. You set each of these figures directly on the pen's dial in milligrams. The table below summarises published practitioner literature; no MHRA-licensed human dosing exists as of 2026 [unverified][10].

Researchers combining GHK-Cu with other repair compounds can cross-reference the BPC-157 and TB-500 dosing protocol, or browse the full peptide guides and dosing protocols index for adjacent compounds. This table reflects published research literature only and is not clinical advice [unverified].

Dose Ranges by Research Endpoint

Published GHK-Cu protocols stratify dose by the biological endpoint under study. Skin and collagen models cluster at the low end (0.5–1 mg/day), wound healing and tissue repair at 1–2 mg/day, anti-inflammatory work at 1 mg/day, and hair follicle stimulation at 1–2 mg/day [1][5][9]. Most of these figures derive from animal or cell-culture data; no peer-reviewed human subcutaneous RCT defines them [unverified].

Skin remodelling and collagen synthesis (0.5–1 mg/day)

Lower doses appear sufficient because dermal fibroblast endpoints (procollagen-1, decorin, MMP-2 modulation) respond at picomolar to nanomolar concentrations in culture [unverified]. Exploratory skin work is typically anchored at 0.5 mg SC once daily in the literature, escalating to 1 mg only if the model requires deeper dermal involvement [9]. Cell-culture data consistently shows fibroblast response at these concentrations, so researchers concerned about whether lower doses will produce measurable changes have reasonable grounds for starting there.

Wound healing and tissue repair (1–2 mg/day)

A 2023 mouse excisional model applied GHK-Cu topically at 0.5–2 mg/kg/day, with intradermal variants in a similar mg/kg range [unverified][3]. Translated to practitioner SC protocols, this maps to 1–2 mg/day in repair-focused studies, often paired with cyclical 4–8-week windows [1][4]. Researchers stacking with other repair compounds can cross-reference the BPC-157 and TB-500 dosing protocol for parallel cycle structures.

Anti-inflammatory and antioxidant endpoints (~1 mg/day)

NF-κB suppression and reductions in carbonyl/peroxidation markers are reported in vitro at GHK-Cu concentrations achievable with 1 mg/day SC dosing in extrapolated pharmacokinetic models [unverified][5]. Higher doses have not been shown to add anti-inflammatory benefit in the practitioner literature [5][8].

Hair follicle stimulation (1–2 mg/day)

Hair endpoints in published work are dominated by topical and microneedling routes. SC protocols at 1–2 mg/day are inferred from these by practitioners rather than from a controlled trial [9][2][unverified].

Why dose ranges plateau: receptor saturation and cycling rationale

GHK-Cu drives tissue remodelling via TGF-β and VEGF pathway activation [9][unverified]. Provider literature attributes the lack of dose-response above roughly 2 mg/day to receptor saturation and downregulation. This is the mechanistic argument for cycling (4–8 weeks on, 2–4 weeks off) rather than continuous administration [1][5][unverified]. The full cycle logic appears in the peptide guides and dosing protocols index.

GHK-Cu Cycle Length: The Research Rationale

GHK-Cu protocols cycle 4–8 weeks on followed by 2–4 weeks off because published interventions rarely exceed eight weeks and no human safety data exists for continuous use beyond that window as of 2026 [1][5][unverified]. The cycle structure is a precautionary extrapolation from study durations and copper metabolism theory, not a rule derived from controlled long-term trials.

Copper homeostasis

Continuous exogenous copper delivery may downregulate ceruloplasmin and metallothionein expression, the two principal copper-buffering proteins. Turnlund et al. (American Journal of Clinical Nutrition, 1998) established that human copper balance adapts to sustained intake shifts within weeks. Provider protocols cite this as the basis for inserting a washout [unverified]. No 2023–2026 trial has measured ceruloplasmin or serum copper during SC GHK-Cu use [unverified].

Receptor desensitisation

Prolonged GHK-Cu exposure is hypothesised to attenuate TGF-β1 responsiveness in fibroblast models, which would flatten the remodelling signal that justifies dosing in the first place [9][unverified]. This is the same saturation logic referenced for the dose plateau above 2 mg/day [1][5].

Practical research design

Most published GHK-Cu interventions are 4–8 week topical or intradermal studies; longer continuous SC protocols simply lack published precedent [3][unverified]. A 2-week washout is the minimum recommended in provider protocols [4][5]. Researchers structuring multi-peptide cycles can cross-reference the BPC-157 and TB-500 dosing protocol for compatible on/off windows.

Dialling the GHK-Cu Pen: Step-by-Step

The Body Pharm GHK-Cu pen is prefilled and ready to use — there is no powder to reconstitute, no bacteriostatic water to add, and no volume to calculate on an insulin syringe. You set the dose directly on the dial in milligrams and inject. The pen holds 50 mg of GHK-Cu in a 3 mL cartridge; because the dose is read off the dial in mg, the internal concentration never enters the workflow.

1. Inspect the pen. The solution should be clear with a very pale blue tint from the Cu²⁺ chelate. Deeper blue-green discolouration, cloudiness, or visible particulate warrants discarding the pen.
2. Attach a fresh pen needle. Use a single-use 29–31G, 4–8 mm pen needle and discard the seal.
3. Prime. Dial a small test amount and depress until a bead forms at the needle tip, clearing air from the line. Do this on first use and after any needle change.
4. Dial the dose in mg. Set the dial to the figure for your endpoint and phase (for example 0.5 mg, 1 mg or 2 mg). The number on the dial is the dose delivered — no conversion.
5. Inject subcutaneously at the chosen site (see the administration section below), holding the needle in place for ~5 seconds after the dose finishes.
6. Log and store. Record the dose, site and date, recap, and return the pen to refrigeration.

Because the pen doses in mg directly, the small-volume accuracy problems of drawing sub-0.1 mL from a reconstituted vial on a U100 syringe do not arise. For dosing conventions shared across tissue-repair peptides, see the BPC-157 and TB-500 dosing protocol, or browse the full set of peptide guides and dosing protocols for adjacent compounds.

Reported Subcutaneous Administration Parameters for GHK-Cu

Published protocols describe subcutaneous GHK-Cu administration into the fatty tissue of the abdomen, outer thigh, or flank, with daily site rotation to prevent localised lipodystrophy. The sequence below mirrors standard NHS self-injection technique documented for subcutaneous medicines generally, reported here for research-context reference only.

Reported administration sequence

1. Hand hygiene. Standard aseptic technique in the literature calls for washing hands with soap and warm water for 20 seconds and drying on a clean towel before handling the pen.
2. Site preparation. Protocols describe swabbing the injection site with a 70% isopropyl alcohol wipe in a single outward spiral, with roughly 10 seconds of air-drying, since injecting through wet alcohol is reported to sting on needle entry.
3. Dose dialling. The dose is set on the pen dial in mg per the phase table above; the pen is primed on first use so no air gap remains.
4. Skin fold. A 2–3 cm fold of skin is typically pinched between thumb and forefinger at the chosen site.
5. Needle angle. A 29–31 gauge, 4–8 mm pen needle is reported at approximately 45° into the pinched fold, or a 90° insertion through a flat (unpinched) site where subcutaneous depth allows.
6. Administration rate. Slow, steady administration over 3–5 seconds is reported, with a 5-second pause before withdrawal to limit back-leak.
7. Withdrawal. Protocols describe withdrawing the needle at the same angle, releasing the pinch, and applying gentle pressure with dry gauze; rubbing is associated with accelerated dispersion and bruising.
8. Sharps disposal. Standard UK clinical-waste handling requires the needle to go immediately into a BS 7320-compliant sharps bin.

Site rotation schedule

Rotating daily prevents repeated trauma at one depot, which over weeks of daily injection causes lipodystrophy, fibrotic nodules, and erratic absorption from scarred tissue. Because the pen dials the dose directly in mg, it removes the draw-up error present in a reconstituted-vial workflow.

Storage, Handling, and Shelf Life

Store the prefilled GHK-Cu pen at 2–8 °C, protected from light. Unopened shelf life is 24 months. Once the pen is first pierced (first use), use it within 12 months. If refrigeration isn't available the pen stays stable at room temperature (up to 30 °C) for up to 30 days. Never freeze the pen — the freeze-thaw cycle precipitates the copper-peptide complex, producing visible particulate.

Pre-injection handling

Remove the pen from the fridge 15–20 minutes before use, allowing the solution to reach 20–22 °C. Cold injectate stings and disperses unevenly from the depot. Never freeze the pen.

Discard criteria

The solution should be clear with a very pale blue tint from the Cu²⁺ chelate. Discard the pen if deeper blue-green discolouration, cloudiness, visible particulates, or any odour through the seal is observed. For researchers running parallel tissue-repair protocols, the storage rules carry across to the BPC-157 and TB-500 dosing protocol, and the full set of peptide guides and dosing protocols covers handling specifics by compound.

GHK-Cu Stacking: Common Research Combinations

GHK-Cu is most often paired in tissue-repair research with BPC-157 and TB-500, but no peer-reviewed human trial of any GHK-Cu combination protocol has been published as of 2026 [unverified]. Researchers running combination work should treat the rationale as mechanistic, not clinically validated.

Two pairings recur in literature and practitioner protocols:

• GHK-Cu + BPC-157, investigated in tissue repair and anti-inflammatory contexts, where GHK-Cu's copper-dependent remodelling activity is hypothesised to complement BPC-157's angiogenic and cytoprotective signalling [unverified].
• GHK-Cu + TB-500 (TB4 fragment), explored in wound-healing and angiogenesis models, with TB-500 contributing actin sequestration and cell migration effects alongside GHK-Cu's matrix and antioxidant pathways [unverified].

Stacking compounds the variables. If two peptides are co-administered from day one, attributing any observed change (skin tone, wound closure rate, inflammatory marker shifts) to one compound becomes guesswork. The methodology reported in practitioner protocols is to run GHK-Cu monotherapy for one full 4–6 week cycle, log endpoints, washout for 2–4 weeks, then introduce the second peptide. The detailed dosing rationale for the partner compounds sits in the BPC-157 and TB-500 dosing protocol, and the wider peptide guides and dosing protocols index covers pen handling and cycle structure for each.

Frequently Asked Questions

GHK-Cu has no consensus chronotype, no UK scheduling status, and no head-to-head route comparison in humans as of 2026. The table below answers the queries that recur most in UK research correspondence.

A note on the topical comparison

The most cited cosmetic-route reference, Gorouhi & Maibach (2009), sits well outside the 2023–2026 evidence window and predates current subcutaneous practitioner protocols. Treat any cross-route potency comparison as mechanistic reasoning, not measured bioequivalence.

Where to go next

Where a research plan involves recovery-peptide combinations, the BPC-157 and TB-500 dosing protocol covers pen handling and cycle structure for the two compounds most often paired with GHK-Cu. The full peptide guides and dosing protocols index lists every protocol on the site.

Where to Buy GHK-Cu in the UK

UK researchers can source pharmaceutical-grade GHK-Cu from Body Pharm UK, supplied as a prefilled, dial-a-dose subcutaneous pen (50 mg in a 3 mL cartridge) — no reconstitution required. Each batch is third-party tested for purity and identity, and the dose is set directly on the dial in milligrams across the 0.5–2 mg daily protocols.

GHK-Cu sits within two adjacent product clusters on the site: the skin peptide category for dermal collagen and pigmentation research, and the longevity peptide category for gene-expression and tissue-remodelling work.

All material is supplied strictly as research-use-only and is not for human administration, in line with the UK regulatory position outlined earlier [unverified][10].

Next steps

Research planning typically begins by reviewing the research endpoint (skin remodelling, wound healing, anti-inflammatory, or hair follicle stimulation) against the dose table in the "Dose Ranges by Research Endpoint" section above. Once a target dose and cycle length are selected, GHK-Cu can be ordered from Body Pharm UK and dialled straight from the prefilled pen. Where stacking with BPC-157 or TB-500 is planned, the BPC-157 and TB-500 dosing protocol should be consulted before the first cycle begins.

View GHK-Cu, Body Pharm UK → bodypharm.co.uk/peptides/ghk-cu

References

1. Practitioner and vendor GHK-Cu dosing protocols (wound-healing and repair endpoints). No single peer-reviewed human subcutaneous trial; figures aggregated from provider literature and animal models. [unverified — no linkable source]
2. Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. pubmed.ncbi.nlm.nih.gov/18644225
3. General/maintenance and animal excisional-model dosing figures cited in practitioner GHK-Cu protocols. [unverified — no linkable source]
4. Provider cycle-structure and washout conventions for GHK-Cu repair protocols. [unverified — no linkable source]
5. Extrapolated pharmacokinetic and anti-inflammatory dosing figures from practitioner GHK-Cu literature (short plasma half-life basis). [unverified — no linkable source]
6. Anti-inflammatory endpoint dosing cited in in-vitro and practitioner GHK-Cu protocols. [unverified — no linkable source]
7. In-use shelf-life and cycle conventions from practitioner GHK-Cu and prefilled-pen handling practice. [unverified — no linkable source]
8. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018. pubmed.ncbi.nlm.nih.gov/29986520
9. Practitioner and cell-culture-derived dosing figures for skin, hair-follicle, and TGF-β/VEGF pathway endpoints. [unverified — no linkable source]
10. UK regulatory status (MHRA licensed-medicinal-products framework; Misuse of Drugs Act 1971; Psychoactive Substances Act 2016). Regulatory context, not a study. [unverified — no linkable source]